1.Appropriate use of Prostate-Specific Antigen in Diagnosing Carcinoma of the Prostate.
Yun Sik KWAK ; Young Ae LIM ; Hee Sun JEON
Journal of the Korean Geriatrics Society 1997;1(1):12-17
No abstract available.
Prostate*
;
Prostate-Specific Antigen*
2.In Search of a New Prostate-Specific Antigen
International Neurourology Journal 2019;23(1):3-4
No abstract available.
Prostate-Specific Antigen
3.Multicenter Comparison of Four Automated Immunoassay Analyzers for Prostate Specific Antigen
Dong Jin PARK ; Yeongsic KIM ; Hae Kyung LEE ; Jehoon LEE ; Kyungja HAN ; Hi Jeong KWON
Annals of Laboratory Medicine 2019;39(4):406-410
No abstract available.
Immunoassay
;
Prostate
;
Prostate-Specific Antigen
4.The Factors Influencing the Percentage of Free Serum Prostate Specific Antigen Levels in Men without Clinically Detectable Prostate Cance.
Dae Young KIM ; Cheol KWAK ; Seung Bae LEE ; Eun Chan PARK ; Hyeon JEONG ; Sang Eun LEE
Korean Journal of Urology 2000;41(6):718-724
No abstract available.
Humans
;
Male
;
Prostate*
;
Prostate-Specific Antigen*
5.The Factors Influencing the Percentage of Free Serum Prostate Specific Antigen Levels in Men without Clinically Detectable Prostate Cance.
Dae Young KIM ; Cheol KWAK ; Seung Bae LEE ; Eun Chan PARK ; Hyeon JEONG ; Sang Eun LEE
Korean Journal of Urology 2000;41(6):718-724
No abstract available.
Humans
;
Male
;
Prostate*
;
Prostate-Specific Antigen*
6.The Effect on Serum Prostate Specific Antigen after Transurethral Resection of Prostate for Benign Prostate Hypertrophy.
Hee Jong JEUNG ; Bong Ryoul OH ; Jai Dong MOON
Korean Journal of Urology 1997;38(1):70-75
PURPOSE: It is important to know for transurethral resection of prostate (TURP) affecting the serum prostate specific antigen (PSA) value how long one should wait before being able to ~ obtain an accurate and meaningful serum PSA level. We evaluated the change of serum PSA concentration in patients with benign prostate hypertrophy(BPH) before and after TURP in association with time course and resected prostatic weight. MATERIALS AND METHOD: The effect of TURP was examined in 27 patients with BPH (mean age: 64 years; range: 55-79 years). The serum PSA levels were measured serially (before and 1, 3, 5, 7, 14, 30, 60, 90 days after TURP) by Abott IMX assay. RESULTS: The level of serum PSA appeared to be consistent with prostatic volume by transrectal ultrasonography(TRUS) and was elevated by about 0.16 ng/mL for each gram of hyperplastic tissue present (p=0.375, p=0.058). TURP caused an immediate elevation in the serum PSA concentration, with a median increase of 19 ng/mL (p=0.0001). The larger resected group showed a dramatic and statistically significant PSA rise immediately after TURP than the smaller resected group (p=0.023). From the 15 post-operative day, the PSA concentrations continued slightly lower than that of pre-operative day (p=0.0001), and was still decreased on 30 days (p=0.0001). The median time to return to a baseline level of PSA was 30 days (range: 1460 days) after TURP. CONCLUSION: These findings indicate that TURP caused an immediate increase in the serum PSA level, which generally return to stable, baseline level within 30 days. However, because in some patients the serum PSA still remained elevated than upper normal limit after 30 days, it is recommended that a serum PSA determination should be obtained for at least 60 days after TURP.
Humans
;
Hypertrophy*
;
Prostate*
;
Prostate-Specific Antigen*
;
Transurethral Resection of Prostate*
7.The Effect on Serum Prostate Specific Antigen after Transurethral Resection of Prostate for Benign Prostate Hypertrophy.
Hee Jong JEUNG ; Bong Ryoul OH ; Jai Dong MOON
Korean Journal of Urology 1997;38(1):70-75
PURPOSE: It is important to know for transurethral resection of prostate (TURP) affecting the serum prostate specific antigen (PSA) value how long one should wait before being able to ~ obtain an accurate and meaningful serum PSA level. We evaluated the change of serum PSA concentration in patients with benign prostate hypertrophy(BPH) before and after TURP in association with time course and resected prostatic weight. MATERIALS AND METHOD: The effect of TURP was examined in 27 patients with BPH (mean age: 64 years; range: 55-79 years). The serum PSA levels were measured serially (before and 1, 3, 5, 7, 14, 30, 60, 90 days after TURP) by Abott IMX assay. RESULTS: The level of serum PSA appeared to be consistent with prostatic volume by transrectal ultrasonography(TRUS) and was elevated by about 0.16 ng/mL for each gram of hyperplastic tissue present (p=0.375, p=0.058). TURP caused an immediate elevation in the serum PSA concentration, with a median increase of 19 ng/mL (p=0.0001). The larger resected group showed a dramatic and statistically significant PSA rise immediately after TURP than the smaller resected group (p=0.023). From the 15 post-operative day, the PSA concentrations continued slightly lower than that of pre-operative day (p=0.0001), and was still decreased on 30 days (p=0.0001). The median time to return to a baseline level of PSA was 30 days (range: 1460 days) after TURP. CONCLUSION: These findings indicate that TURP caused an immediate increase in the serum PSA level, which generally return to stable, baseline level within 30 days. However, because in some patients the serum PSA still remained elevated than upper normal limit after 30 days, it is recommended that a serum PSA determination should be obtained for at least 60 days after TURP.
Humans
;
Hypertrophy*
;
Prostate*
;
Prostate-Specific Antigen*
;
Transurethral Resection of Prostate*
8.The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend.
Hyung Sang KIM ; Chang Yong LEE ; Dong Hun LIM ; Chul Sung KIM ; Seung BAIK
Korean Journal of Urology 2012;53(10):686-690
PURPOSE: To identify the prostate cancer detection rate on the patients who had second prostate biopsy out of the patients who were reported negative in their first biopsy. MATERIALS AND METHODS: From July 2006 to February 2012, prostate biopsy was performed on 843 patients with over 4 ng/ml and on 618 biopsy negative patients PSA was performed from between 6 months and 9 months after biopsy. On 164 patients, second biopsy was performed, and 42 patients were selected. If there was less than 10% change between PSA before the prostate biopsy and PSA measured during 6 to 9 months after the first biopsy it was considered as no change. If above 10% increase, it was considered increase and if above 10% decrease it was considered as decrease. RESULTS: The cancer detection rate in PSA increase group was 20%, the detection rate in no change in PSA level but still over the normal range group 8.3%, and that in the PSA decrease group was 0%. When comparing prostate cancer group and non-cancer group, it is more probable to have prostate cancer when they are older, prostate volume is smaller and PSA density is higher. CONCLUSIONS: The second biopsy is strongly recommended when PSA level shows no change or increase, age is older, prostate volume is smaller or PSA density is higher.
Biopsy
;
Humans
;
Prostate
;
Prostate-Specific Antigen
;
Prostatic Neoplasms
;
Reference Values
9.Prostate Specific Antigen Density (PSAD) in the Detection of the Prostate Cancer.
Eun Ho CHOI ; Choung Soo KIM ; Tai Young AHN
Korean Journal of Urology 1995;36(9):911-916
Prostate specific antigen(PSA) is an extremely valuable tumor marker. However, its use in detection of prostate cancer is limited by low sensitivity and specificity. To enhance the accuracy of serum PSA we used the quotient of serum PSA and prostate volume, which is referred to as prostate specific antigen density(PSAD). Prostate volume in this study was calculated from transrectal ultrasonographic determinations using the formula, length x width x depth x 0.52 = volume. The serum PSA was analyzed using the Hybritech assay. Prostate biopsy was performed transperineally from at least six sites. The cancer detection rate was 3.3%(three out of 91 patients) in the group with PSA value of less than 4.0ng/ml and 11.3%(eight out of 71 patients) in the group with PSA value of 4.1 to 10. 0ng/ml. In the latter group, mean PSA value for the positive(n=8) and negative(n=63) biopsy group was 7.10+/-1.22 and 6.61+/-1.79ng/ml each(p=0.4630), but mean PSAD value was 0.275+/-0.089 and 0.187+/-0.078 each(p=0.0045). In the group of 38 patients with PSA value of 10.1 to 20.0ng/m1, the cancer detection rate was 15.8%(six patients) and the mean PSA value for the positive(n=6) and negative(n=32) biopsy group was 15.5+/-3.09 and 13.4+/-2.78ng/ml each(p=0. 1038), but the mean PSAD value was 0.535+/-0.082 and 0.334+/-0.182 each(p=0.0128). These results suggest that PSAD be useful in distinguishing BPH and prostate cancer in the patients with intermediate PSA values(4.1ng/ml to 20.0ng/ml).
Biopsy
;
Humans
;
Prostate*
;
Prostate-Specific Antigen*
;
Prostatic Neoplasms*
;
Sensitivity and Specificity
10.Effect of transrectal prostatic biopsy on serum prostate specific antigen levels.
Ze-Qiao XU ; Li-Xin HUA ; Li-Xin QIAN ; Hong-Fei WU
National Journal of Andrology 2002;8(5):341-342
OBJECTIVESTo assess the effect of transrectal prostatic biopsy (TPB) on the concentrations of serum prostate specific antigen (PSA).
METHODSTwenty patients with abnormal PSA levels and/or digital rectal examination (DRE) underwent TPB. Serum PSA levels were measured before TPB and at 0.5 h, 1 week, 1 month after TPB, respectively.
RESULTSThe serum PSA levels before TPB and 0.5 h, 1 week, 1 month after TPB were (12.23 +/- 8.62), (34.90 +/- 41.53), (23.59 +/- 20.78) and (11.31 +/- 6.95) micrograms/L, respectively. The serum PSA concentration was significantly higher at 0.5 h after TPB than before (P < 0.05), and then gradually decreased. PSA levels remained higher for at least 1 week in 85% (17/20) patients(P < 0.05), then returned to the baseline at one month after TPB (P > 0.05).
CONCLUSIONSTPB can lead to a dramatic increase of PSA in serum and keep the PSA value high in one week. Then the PSA in serum decreased gradully. Serum PSA level cannot return to baseline until one month after TPB.
Biopsy ; Humans ; Male ; Prostate ; pathology ; Prostate-Specific Antigen ; blood